Entries |
Document | Title | Date |
20100286061 | PLASMIN-INHIBITORY THERAPIES - The disclosure features a method of treating cancers, angiogenesis-related disorders and lymphangiogenesis-related disorders with plasmin inhibitors. An exemplary method includes: administering, to a subject, a plasmin inhibitor, such as a protein that includes a Kunitz domain that inhibits plasmin. | 11-11-2010 |
20100286062 | PHARMACEUTICAL COMPOUND - Provided is a compound comprising:
| 11-11-2010 |
20100292166 | PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMORS CONTAINING HUMAN p31 GENES - A pharmaceutical composition for the treatment of malignant tumors comprising a human p31 | 11-18-2010 |
20100292167 | C-MET KINASE BINDING PROTEINS - Polypeptides comprising monomer domains that bind to c-MET, or portions thereof, are provided. | 11-18-2010 |
20100317593 | 2,3-DIHYDRO-1H-INDENE COMPOUNDS - Provided herein are 2,3-dihydro-1H-indene compounds, methods for making the compounds, pharmaceutical compositions containing the compounds. The described compounds inhibit IAP proteins and can be used to treat various cancers. | 12-16-2010 |
20100317594 | Methods for treating breast cancer using NRIF3 related molecules - Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to all members of the NRIF3 family. Two other death domains (DD2 and DD3) were also found to have effective breast cancer killing activities. Mechanistic studies showed that DD1-induced apoptosis occurred through a novel caspase-2 mediated pathway that involved mitochondria membrane permeabilization but did not require other caspases. Interestingly, cytotoxicity of NRIF3 related molecules was cell-type specific, as they selectively killed breast cancer or related cells but not other examined cells of different origins, suggesting the presence in breast cancer cells of a specific death switch that can be selectively triggered by NRIF3 and related molecules. Also disclosed are strategies utilizing NRIF3 related molecules and/or targeting this death switch for the development of novel and more selective therapeutics against breast cancer. | 12-16-2010 |
20110003753 | COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER - The present invention relates, generally, to compositions for treating breast cancer, use of the compositions to sensitize breast cancer cells to treatment, and methods for treating breast cancer by administering the compositions. The compositions comprise peptides derived from the mSin3A interaction domain (SID) and derivatives thereof, as well as small molecule inhibitors (SMIs) capable of interfering with interactions between SID and the paired amphipathic helix domain 2 (PAH2) domain of the transcription repressor Sin3A. The present invention further relates to compositions for treating triple-negative breast cancer, use of the compositions to render the breast cancer cells susceptible to treatment using hormonal therapies and HER2-based therapies, and methods for treating triple-negative breast cancer by administering the compositions. | 01-06-2011 |
20110003754 | Peptide-Conjugated Oligonucleotide Therapeutic and Method of Making and Using Same - Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: | 01-06-2011 |
20110009336 | Treatment of Cancers with Immunostimulatory HIV TAT Derivative Polypeptides - Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide. | 01-13-2011 |
20110015135 | Antitumoral Treatments - The present invention relates to combinations of PM02734 with another anticancer drug selected from Cisplatin, Gemcitabine, Paclitaxel, Oxaliplatin, 5-Fluorouracil, Trabectedin, Rapamycin, and Sunitinib, and the use of these combinations in the treatment of cancer. | 01-20-2011 |
20110039788 | COMPOSITIONS, METHODS AND KITS FOR DETECTING AND TREATING CANCER - Compositions, kits and methods for inhibiting cancer cell (e.g., breast cancer cell) growth and treating a subject with cancer (e.g., breast cancer) include a therapeutically effective amount of an LBH inhibitor for inhibiting cancer cell growth and a pharmaceutically acceptable carrier, and/or a therapeutically effective amount of Wnt7a protein or nucleic acids encoding Wnt7a protein for inhibiting cancer cell growth and a pharmaceutically acceptable carrier. Methods of treating a subject having cancer (e.g., estrogen receptor negative basal-type breast cancer) include administering to the subject a composition including a pharmaceutical carrier and at least one of: an LBH inhibitor, a WNT7a protein, and a nucleic acid encoding WNT7a protein in an amount effective for inhibiting growth of cancer cells in the subject. Methods of detecting the presence of cancer (e.g., estrogen receptor negative basal-type breast cancer) in a subject include obtaining a biological sample from the subject; contacting the sample with at least one reagent that detects presence of LBH expression; measuring the level of LBH expression in the biological sample; and correlating overexpression of LBH with the presence of cancer (e.g., estrogen receptor negative basal-type breast cancer) in the subject. Kits for detecting the presence of basal-type breast cancer in a subject include at least one reagent for detecting the presence of LBH expression in a biological sample from the subject and instructions for use. | 02-17-2011 |
20110039789 | Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer - The present invention relates to new methods of treatment of cancer, in particular of breast cancer, and methods of screening of compounds useful in the treatment of cancer. The present invention further provides new prognostic and/or diagnostic markers in human cancer. | 02-17-2011 |
20110046071 | GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer - Disclosed are methods and compositions for increasing concentrations of GLP-1 receptor agonists in the body for the treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents. | 02-24-2011 |
20110053863 | METHODS OF USING FLT3-LIGAND IN THE TREATMENT OF CANCER - Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation. | 03-03-2011 |
20110053864 | Compositions and methods for modulation of cell migration - A peptide includes SEQ ID NO:3, substitution and addition variants thereof which maintain the ability to activate CD44. A complex includes this peptide or an Å6 polypeptide with a CD44 polypeptide. An isolated polypeptide includes the Link region sequence of human CD44, functionally active fragments thereof, substitution variants, and addition variants. A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3 or an Å6 polypeptide to bind to a CD44 polypeptide and modulate signal transduction activity for a sufficient period of time to treat the disease. Other methods include using the peptide of SEQ ID NO:3 or an Å6 polypeptide for diagnosing, identifying a subpopulation of subjects responsive to treatment, and screening for compounds that bind a CD44 polypeptide. | 03-03-2011 |
20110092442 | Anticancer agent containing bl-angiostatin - An anticancer agent containing BL-angiostatin as an active ingredient; and a process for producing the same. Also a method for treating cancer comprising administering to a mammal a pharmaceutically effective amount of BL-angiostatin. | 04-21-2011 |
20110098234 | BREAST CANCER PROTEINS - The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member of a given pool. Besides, the invention refers to proteins whose abundances are upregulated in cancer cells, especially in breast cancer cells, preferably in breast cancer cells that are positive or negative towards hormone binding receptors. | 04-28-2011 |
20110098235 | ANTINEOPLASTIC PEPTIDES - The present invention provides antineoplastic peptides of formula I, | 04-28-2011 |
20110118192 | METHODS AND COMPOSITIONS FOR TREATING T-CELL LEUKEMIA - The present invention relates to compositions and methods that may be used to diagnose and treat cancer, particularly T-cell leukemia. According to one preferred embodiment of the present invention, methods are provided for determining whether reducing or blocking NOTCH-1 activation will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient, including T-cell leukemia, myeloleukemia, neuroblastoma, breast cancer, and ovarian cancer. The methods generally include determining if the patient harbors one or more mutations in a PTEN coding region. In particular, the methods may be used to determine whether reducing or blocking NOTCH-1 activation, with one or more γ-secretase inhibitors, will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient. | 05-19-2011 |
20110124574 | RESTORATION OF ESTROGEN RECEPTOR-(ALPHA) ACTIVITY - One third of all breast cancers are estrogen receptor alpha (ERα) negative, have a poor overall prognosis and do not respond well to currently available endocrine therapies. Use of a Wnt5-α protein or a peptide thereof, such as a recombinant Wnt-5a protein or a Wnt-5a derived hexapeptide (Foxy-5) possessing Wnt-5a signaling properties, enables restoration of ERα expression and makes it possible to treat such breast cancers with selective estrogen receptor modulators, such as tamoxifen, or aromatase inhibitors. | 05-26-2011 |
20110130344 | TIGHT JUNCTION PROTEIN MODULATORS AND USES THEREOF - The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin. | 06-02-2011 |
20110152200 | METHODS AND COMPOSITIONS FOR INHIBITION OF BCL6 REPRESSION - The invention is directed to a compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove. The present invention is further directed to methods for blocking corepressor binding to a BCL6 lateral groove, methods for inhibiting BCL6 repression in a mammalian cell, and methods for treating a mammal with cancer, wherein the cancer requires BCL6 repression. The present invention is further directed to polypeptides comprising a portion of the corepressor binding site for BCL6 and related polynucleotides and vectors. | 06-23-2011 |
20110166079 | METHODS OF TREATING CANCER WITH APOE PEPTIDES - Methods of treating chronic lympocytic leukemia, chronic myelogenous leukemia, and breast cancer in a subject by administering an ApoE peptide are disclosed. | 07-07-2011 |
20110172163 | Novel Protease Inhibitors - The invention relates to KLK protease inhibitors. In particular, the invention is directed to KLK4 protease inhibitors and their uses in the treatment of a cancer, such as prostate cancer. | 07-14-2011 |
20110190218 | BAG-1 PEPTIDE THAT INHIBITS PROSTATE CANCER - The present invention relates to a polypeptide having antitumor properties, to a vector encoding said polypeptide, to a host cell containing said vector, to uses of said polypeptide in the manufacture of a medicament for the treatment of cancer in patients, to a method comprising binding said polypeptide to molecular chaperones, and to a pharmaceutical composition containing said polypeptide. | 08-04-2011 |
20110224149 | POLYNUCLEOTIDES FOR USE IN TREATING AND DIAGNOSING CANCERS - The present invention provides methods for increasing sensitivity of cancer cells to an antiestrogen agent, such as a selective estrogen receptor modulator (SERM). The methods include administering to the subject a polynucleotide in an amount effective to increase the antiestrogen agent sensitivity of the cancer cells. The cancer cells may be estrogen receptor positive, such as ER-α66 positive or ER-α36 positive, prior to the administering. Also provided are methods for decreasing the amount of estrogen receptor present in a cancer cell, methods for determining whether antiestrogen agent sensitivity of cancer cells in a subject can be increased, methods for diagnosing whether a subject has, or is at risk for developing, cancer, and methods for identifying an agent that increases the amount of let-7 miRNA in a cell. | 09-15-2011 |
20110230421 | FUSION PROTEINS OF APOPTIN-PROTEIN TRANSDUCTION DOMAIN OF CARBOXYL-TERMINUS OF EC-SOD - Provided are fusion proteins of apoptin-protein transduction domain of carboxyl-terminus of EC-SOD, their encoding genes, the recombinant vectors containing said encoding genes, transformants containing said recombinant vectors, as well as the uses and preparation methods thereof. Especially provided are fusion proteins which fuse protein transduction domain of carboxyl-terminus of EC-SOD in the amino acid sequence of SEQ ID NO:1 or its mutants and apoptin in the amino acid sequence of SEQ ID NO:2 or its mutants, said fusion proteins have strong ability of inducing apoptosis of tumor cells, and can be used for manufacturing of medicament for the treatment of tumors. | 09-22-2011 |
20110288032 | ENZASTAURIN FOR THE TREATMENT OF CANCER - The present invention relates to HDAC2 as a biological marker for treating cancer in a patient using Enzastaurin as a single agent or in combination with a Class I selective HDAC inhibitor. | 11-24-2011 |
20110319338 | PEPTIDES THAT BIND EUKARYOTIC TRANSLATION INITIATION FACTOR 4E - Methods, compositions and kits for treating proliferative and non-proliferative diseases associated with abnormal protein synthesis. Chimeric peptide constructs are comprised in compositions and kits for use in the treatment of proliferative diseases, such as ovarian cancer, and for inhibiting protein synthesis in a tumor cell compared to a non-tumor cell. | 12-29-2011 |
20120004182 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR INDUCTION AND ENHANCEMENT OF APOPTOSIS IN TUMOR CELLS - The present invention relates to methods for inducing and/or enhancing apoptosis in pathogenic cells. In particular, the present invention relates to the use of GnRH II antagonists in combination with at least one further compound selected from the group of selective estrogen receptor modulators (SERM), Aromatase inhibitors, and glycolysis inhibitors or salts or solvates thereof for inducing and/or enhancing apoptosis of specific types of tumor cells, expressing the GnRH II receptor as well as to methods relating thereto. | 01-05-2012 |
20120010153 | NOVEL TUMOR-TARGETING COMPOUNDS - The invention relates to a novel compounds targeting human cancer cells, a method for synthesis of such compounds, and use of such compounds in treating cancer. | 01-12-2012 |
20120010154 | Cytotoxic Conjugates Having Neuropeptide Y Receptor Binding Compound - There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors. | 01-12-2012 |
20120028909 | FN14/TRAIL Fusion Proteins - Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer, | 02-02-2012 |
20120040915 | PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer. | 02-16-2012 |
20120065147 | USE OF THE GTPASE RAB27B TO DIAGNOSE AND TREAT POOR PROGNOSIS ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER - The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for drugs capable of inhibiting or diminishing metastasis of said cancer. Furthermore, the invention discloses compounds which can be used to treat estrogen receptor-positive breast cancer. | 03-15-2012 |
20120094925 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 FOR TREATMENT OF CANCER - Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS. | 04-19-2012 |
20120108522 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER - The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone resistant cancers to hormonal therapeutic agents. In particular embodiments, the present invention concerns delivery of a histone deacetylase inhibitor and a hormone targeted drug to an individual with cancer. In specific embodiments, the histone deacetylase inhibitor and the hormone targeted drug act synergistically to treat the cancer, including by overcoming resistance to a cancer therapy. | 05-03-2012 |
20120142606 | TUMOR TARGETING PEPTIDES, THERAPEUTIC AND DIAGNOSTIC COMPOSITIONS COMPRESSING THE PEPTIDES - The present invention is directed to peptides having affinity for tumor cells. The peptides are useful in pharmaceutical compositions in particular for the treatment of cancer. Further, the peptides are useful in diagnostic compositions, in particular for the diagnosis and imaging of cancer. The peptides according to the present invention are peptides selected from the group consisting of: Z | 06-07-2012 |
20120172313 | TREATMENT OF PROLIFERATIVE DISEASES - The present invention relates to methods for preventing or treating proliferative diseases. In particular, the present invention relates to the use of compositions derived or derivable from plants, such as plant defensins, particularly in methods for the prevention or treatment of proliferative diseases such as cancer. The present invention also relates to associated uses, systems and kits. | 07-05-2012 |
20120172314 | Klotho Protein and Related Compounds for the Treatment and Diagnosis of Cancer - Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents. | 07-05-2012 |
20120178699 | KLOTHO PROTEIN AND RELATED COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF CANCER - Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents. | 07-12-2012 |
20120208769 | Chemokine-Mucin Fusions Linked to Glycosylphosphatidylinositol (GPI)-Anchors in Tissue Regeneration and as Tumour Immune Adjuvants - The present invention relates to chemokine-mucin fusions linked to glycosylphosphatidylinositol (GPI)-anchors and their use as anti-cancer adjuvants and as agents in tissue regeneration and suppression of vascular damage. GPI-linked chemokines are incorporated in the surface membrane of tumour cells and effect a recruitment of cytotoxic immune cells to the tumour site following injection in vivo. Leukocytes, cytotoxic T-cells and NK cells target the chemokine-GPI-anchored tumour cells and modulate cell-mediated lysis of the tumour cells. The efficiency of GPI-anchoring and modulation of immune cells can be further enhanced by linking the chemokine to a mucin domain followed by the GPI-anchor. The GPI-anchored chemokines, with or without mucin domain, are remarkably useful for the inhibition of tumour growth, tissue regeneration, and suppression of acute vascular damage to allografts. | 08-16-2012 |
20120208770 | Carcinoma Homing Peptide (CHP), Its Analogs, and Methods of Using - A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments. | 08-16-2012 |
20120214744 | POLYPEPTIDES AND NUCLEIC ACIDS FOR TREATING ERBB2-DEPENDENT CANCERS - The present invention relates to polypeptides, nucleic acids and pharmaceutical compositions suitable for use in the treatment of ErbB2 dependent-cancers, in particular of tumors overexpressing ErbB2 or expressing mutated forms of the ErbB2 gene. | 08-23-2012 |
20120220539 | CONOTOXIN PEPTIDES - The present invention relates conotoxin peptides that are analogs of the α-contoxin peptide RgIA. These conotoxin peptides block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, such as neuropathic pain and inflammatory pain, inflammatory disorders, such as rheumatic diseases, and in the treatment of breast cancer. | 08-30-2012 |
20120220540 | SYNBODIES TO AKT1 - The present application provides synbodies against AKT1 differing in amino acid sequence, conjugation chemistry, linker/scaffold, or adjunct moiety. The synbodies are useful for diagnosis and treatment of cancer and as research reagents. | 08-30-2012 |
20120225825 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 09-06-2012 |
20120270799 | METHOD OF IDENTIFYING A CANDIDATE COMPOUND WHICH MAY INHIBIT a9-nAchR OVEREXPRESSION OR ESTROGEN RECEPTOR-DEPENDENT TRANSCRIPTION IN NICOTINE-DERIVED-COMPOUND-INDUCED BREAST CANCER CELLS - The invention relates to methods of identifying a candidate compound which may inhibit estrogen receptor-dependent transcription or α9-nAChR overexpression and proliferation of nicotine-derived-compound-induced breast cancer cells by using an activating protein 1 (AP1) polypeptide. The invention found that α9-nAChR has an activating protein 1 (AP1)-binding site, that the α9-nAChR promoter is located at the AP1-binding site, and that ERs specifically bind to the α9-nAChR promoter at the AP1-binding site, indicating that ER-induced α9-nAChR up-regulation plays a central role in the response to endogenous (E2) or exogenous (nicotine) stimulation. | 10-25-2012 |
20120270800 | BIFUNCTIONAL STAPLED POLYPEPTIDES AND USES THEREOF - The invention relates to bifunctional stapled or stiched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stiched peptides that bind to an effector biomolecule through the effector domain and bind to a target biomolecule through the targeting domain. Polypeptides and/or polypeptide complexes that are tethered by the bifunctional stapled or stiched peptides of the invention, where the effector polypeptide bound to the effector domain of the bifunctional stapled or stiched peptide modifies or alters the target polypeptide bound to the targeting domain of the bifunctional peptide. Uses of the inventive bifunctional stapled or stiched peptides including methods for treatment of disease (e.g., cancer, inflammatory diseases) are also provided. | 10-25-2012 |
20120270801 | HER3 BINDING POLYPEPTIDES - The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX | 10-25-2012 |
20120302511 | PEPTIDES BINDING TO THE DIMER INTERFACE OF THYMIDYLATE SYNTHASE FOR THE TREATMENT OF CANCER - Provided are peptides that bind to the thymidylate synthase protein, in particular to human thymidylate synthase (hTS) protein, for the treatment of cancer. Further provided are peptides that can bind at a binding site located at the interface of thymidylate synthase protein. These peptides range from 3 to 10, preferably 4-8 amino acids and have a sequence that binds to each subunit of the thymidylate synthase dimer at the level of dimer interface, stabilizing the dimeric inactive form of the thymidylate synthase enzyme. In addition, provided are pharmaceutical compositions including these compounds as active agents, and uses thereof for the treatment of cancer and to reverse or/and be active in cancer drug resistance. | 11-29-2012 |
20120309692 | Activation of Peptide Prodrugs by hK2 - The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention. | 12-06-2012 |
20130040894 | INHIBITION OR ACTIVATION OF SERINE/THREONINE ULK3 KINASE ACTIVITY - The present invention relates to human serine/threonine kinase ULK3 and its ability to regulate GLI transcription factors; mediators of SHH signaling. This disclosure demonstrates that ULK3 enhances endogenous and over-expressed GLI1 and GLI2 transcriptional activity in cultured cells, and ULK3 alters subcellular localization of GLI1. According to this disclosure ULK3 is an autophosphorylated kinase and phosphorylates GLI proteins in vitro. A peptide sequence in GLI1 C-terminus that is phosphorylated by ULK3 is provided in this disclosure. ULK3 catalytical activity is shown to be crucial for its function in SHH pathway. This disclosure shows that serine/threonine kinase ULK3 is involved in the SHH pathway as a positive regulator of GLI proteins. Furthermore, a therapeutic method in SHH dependent human disorders is disclosed by pharmacological inhibition of ULK3 kinase activity. Identification of ULK3 substrate sequence in GLI1 allows the design of peptide-based modulators of its kinase activity. | 02-14-2013 |
20130059794 | ALPHA-FETOPROTEIN "RING AND TAIL" PEPTIDES - The invention relates to compounds that are analogs of a cyclic peptide, cyclo[EKTOVNOGN], AFPep, that has anti-estrotrophic activity. The analogs of the invention include peptides and peptidomimetics that inhibit estrogen receptor-dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer. | 03-07-2013 |
20130079288 | DIFFERENTIAL EFFECTS OF DRUGS ON TRANSPORT IN A MULTI-LAYER 3D SPHEROID MODEL - Drugs are screened for affects on inhibiting efflux pumps and blocking gap junction communication in tumors by culturing cells to thereby form self-assembled spheroids and incubating the spheroids. Uptake of a substrate of the efflux pump and distribution of a substrate for the efflux pump within the spheroids is imaged to thereby select drugs that inhibit the efflux pump or do not block gap junction communication. Selected drugs can then be employed to treat a tumor. | 03-28-2013 |
20130109629 | BLOCKADE OF CCL18 SIGNALING VIA CCR6 AS A THERAPEUTIC OPTION IN FIBROTIC DISEASES AND CANCER | 05-02-2013 |
20130130992 | DIPEPTIDE DERIVATIVE FOR THE TREATMENT OF CANCER - This invention relates to purified compound of formula (1). The invention includes all isomeric forms and all tautomeric forms of the compound of formula (1) and pharmaceutically acceptable salts thereof. The present invention further relates to processes for the production of the compound of formula (1) by fermentation of the fungal strain of sterile mycelium (PM0509732/MTCC5544) and to pharmaceutical compositions containing the compound as active ingredient and its use in medicines for treatment of cancer. | 05-23-2013 |
20130184223 | METHODS AND COMPOSITIONS RELATED TO MODULATING AUTOPHAGY - Disclosed are compositions and methods related to new targets for cancer treatment the modulation of autophagy. | 07-18-2013 |
20130190250 | Polynucleotides Encoding Human Signal Peptide-Containing Proteins - The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP. | 07-25-2013 |
20130225503 | TEX14 PEPTIDES AS NOVEL ANTITUMOR AGENTS - Embodiments of the present invention regard TEX14 peptides for cancer treatment. In particular, the TEX14 peptides comprise a GPPX3Y motif. Methods, compositions, and kits are encompassed. | 08-29-2013 |
20130252905 | PLIF MULTIMERIC PEPTIDES AND USES THEREOF - Provided is a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of Placenta Immunomodulatory Factor (PLIF) to human leukocytes. | 09-26-2013 |
20130274203 | ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention. | 10-17-2013 |
20130288984 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof. | 10-31-2013 |
20130331334 | TARGETED CARGO PROTEIN COMBINATION THERAPY - The present invention combines a targeted cargo protein with an active agent for the treatment of a disease or condition. | 12-12-2013 |
20130331335 | TREATMENT OF CANCERS WITH IMMUNOSTIMULATORY HIV TAT DERIVATIVE POLYPEPTIDES - Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide. | 12-12-2013 |
20130345144 | Use of ID4 for Diagnosis and Treatment of Cancer - Methods for diagnosis and treatment of cancer using ID4 are disclosed. Specifically, epigenetic inactivation of ID4 in colorectal carcinomas and breast correlates with poor differentiation and unfavorable prognosis. Further, aberrant hypermethylation of ID4 gene promoter region increases risk of metastasis in colorectal and breast cancer. | 12-26-2013 |
20130345145 | ATIP3 AND BIOLOGICALLY ACTIVE FRAGMENTS THEREOF FOR USE IN THE TREATMENT OF CANCER - The present invention concerns a combination of (i) a polypeptide comprising ATIP3 or a biologically active fragment thereof, and (ii) a chemotherapeutic drug that is an antimitotic agent, for simultaneous or sequential use in the treatment of a patient suffering from cancer, e.g. a triple-negative breast cancer. The present invention also relates to a polypeptide comprising ATIP3 or a biologically active fragment thereof, for use in sustaining drug effect, increasing or restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug that is an anti-mitotic agent. The present invention further provides biologically active polypeptides that comprise or consist of fragments of ATIP3, and antibodies binding thereto. | 12-26-2013 |
20140051643 | ANTICANCER AGENT - The present invention thus provides microbial products as anticancer agents and pharmaceutical compositions comprising isolated and purified proteins or synthetic peptides, and methods of using them for the treatment of cancer. It is very important to develop new anticancer bioactive peptides having high activity and low toxicity; given that most currently available anticancer therapies either have significant toxicity, and/or are prone to development of resistance. | 02-20-2014 |
20140051644 | PHARMACEUTICAL COMPOSITION FOR TREATING HYPERPROLIFERATIVE DISEASES - The proposed pharmaceutical compositions and methods connected thereto relate to the field of biotechnology and medicine, in particular to pharmaceutical compositions having an antiproliferative activity, and to a method of treating oncologic diseases, which includes introducing the aforementioned chimerical peptide into a mammal requiring such treatment. The object of the proposed compositions and methods is the development of a preparation that effectively penetrates the target cells and has a high cytostatic and cytotoxic action. | 02-20-2014 |
20140066385 | METHOD FOR TREATING CANCER BY COMBINED USE OF DRUGS - A composition and method for cancer treatment comprising FK330 or a salt thereof as an active ingredient, which is for combined administration with one or more anti-tumor agents selected from taxane-family anti-tumor agents, and according to an embodiment, a composition for treatment of prostatic cancer or ovarian cancer. This abstract is not limiting of the invention. | 03-06-2014 |
20140088022 | Novel Solid Materials of and Methods for Obtaining Them - The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals. | 03-27-2014 |
20140088023 | sGCalpha1 Inhibiting Compositions, and Methods of Treatment of Cancers Therewith - The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits. | 03-27-2014 |
20140142044 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE - Novel compounds are provided that bind to polo-like kinases through the polo-box domain. In certain embodiments, the novel compounds are PEGylated peptides. The PEGylated peptides in accordance with the invention demonstrate high PBD-binding affinity. In certain embodiments, the PEGylated peptides have also achieved activities in whole cell systems. The invention also provides compounds that bind polo-like kinases through the polo-box domain and possess reduced anionic charge. Further provided are methods of design and/or synthesis of the PEGylated peptides and methods of use thereof. The invention provides methods of use of the compounds and methods of synthesis of the compounds. The compounds of the invention have potential therapeutic activity in view of their binding and inhibitory activities towards Plk1. They are based on the amino acid sequence PLHSpT (phosphorylated Thr). The PEG moiety, when present, is covalently attached at the N-terminus. The invention also encompasses derivatives having substituents on the Pro and/or the His side chains, substituents on the phosphate group, the replacement of His with Gln, the replacement of Pro with a N-substituted Gly, the replacement of Ser with Ala, as well as HS-pT fragments with N-terminal alkoxycarbonyl group and PLHS fragments with a C-terminal glyco-imino-alkylxyalkylamide group. | 05-22-2014 |
20140142045 | USE OF REGULATOR OF CALCINEURIN 1 FOR MANUFACTURING MEDICAMENT FOR TREATMENT OF DISEASES ASSOCIATED WITH INCREASED NF-KB ACTIVITY - The present invention provides the use of a peptide comprising an amino acid sequence of SEQ ID NO:3, or the encoding nucleic acid thereof, for manufacturing medicament for treatment of diseases associated with increased NF-κB activity. The peptide can interact with IKB and influence phosphorylation of IKB in the tyrosine at position 42, thereby inhibiting the signal pathway of NF-κB. | 05-22-2014 |
20140162960 | Scaffold-Kinase Interaction Blockades and Uses Thereof in Treating Cancer - Aspects of the invention include compositions and methods for inhibiting the interaction between scaffold proteins and kinases. These compositions and methods find a number of uses including, for example, suppressing tumor growth and metastasis and reducing tumor size and number in a mammal with cancer. | 06-12-2014 |
20140187496 | SGEF CONTROLS MACULAR, CORPUS CALLOSUM AND HIPPOCAMPAL FUNCTION AND DEVELOPMENT, LIVER HOMEOSTASIS, FUNCTIONS OF THE IMMUNE SYSTEM, FEVER RESPONSE ATHEROSCLEROSIS AND TUMOROGENIC CELL GROWTH - The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system and diseases including a feverless response to infection, a cancer or vision loss. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene or altered levels of the SGEF mRNA or protein. A change of at least about 20% in the level of expression visa-vie a normal individual indicates an SGEF anomaly. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers. | 07-03-2014 |
20140194368 | Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70) - The invention is directed to methods of treating cancer by administration of heat shock protein 70 (Hsp70) to the subject suffering from cancer. | 07-10-2014 |
20140206621 | Cancer Therapy Method - This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide. | 07-24-2014 |
20140206622 | STABLE PEPTIDE-BASED PACE4 INHIBITORS - It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed. | 07-24-2014 |
20140243275 | Galectin-3C Combination Therapy for Human Cancer - The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses. | 08-28-2014 |
20140243276 | SMAC MIMETIC (BIRINAPANT) FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES (CANCER) - A method of using a Smac mimetic and pharmaceutical compositions thereof. | 08-28-2014 |
20140309174 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER - The present invention provides compounds having formula (I): | 10-16-2014 |
20140329760 | PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer. | 11-06-2014 |
20140342994 | Fusion Protein Comprising Circularly Permuted Form Of Trail/Apo2L, Coding Gene And Use Thereof - Provided is a fusion protein comprising circularly permuted form of TRAIL, and the fusion protein contains circularly permuted form of TRAIL and oligopeptides located at the N-terminus and/or C-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines. The components of the circularly permuted form of TRAIL from N-terminus to C-terminus are: (a) amino acids 135-281 of TRAIL, (b) a linker, and (c) amino acids 121-135 of TRAIL or amino acids 114-135 of TRAIL or amino acids 95-135 of TRAIL or any fragments of amino acids 95-135 of TRAIL containing amino acids 121-135 of TRAIL. Also provided is a method for treating cancer by using the fusion protein. | 11-20-2014 |
20140364376 | CELL-PENETRATING PEPTIDES - The invention relates to a cell-penetrating peptide, optionally linked to a pro-apoptotic peptide, useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors. | 12-11-2014 |
20140371158 | BEAUVERICIN COMPOSITIONS AND METHODS THEREOF FOR INHIBITING THE HSP90 CHAPERONE PATHWAY - Methods of inhibiting the Hsp90 chaperone pathway including contacting one or more target cells with an effective amount of a naturally occurring beauvericin, a synthetic beauvericin, or a derivative, analog or prodrug, or a pharmacologically active salt thereof to reduce, decrease, or inhibit the Hsp90 chaperone pathway in the cells compared to a control are disclosed. The methods can reduce the viability of the target cells, for example, by increasing apoptosis or pro-apoptotic pathways. In preferred embodiments, the methods reduce or do not increase Hsp70, Hsp24, Hsp40, or HOP expression; reduce or do not increase the heat shock response; reduce or do not increase pro-survival pathways in the cells. Methods of treating diseases such as cancer, inflammatory diseases or disorders, neurodegenerative diseases, and infectious diseases using the disclosed compositions and methods are also disclosed. | 12-18-2014 |
20150031626 | ADAM22 FOR USE AS A PROGNOSTIC VARIABLE, AND TARGET FOR THERAPY, OF A METASTATIC BREAST CANCER DISEASE - A method of diagnosing metastatic potential of a breast cancer in an individual with breast cancer is described. The method comprises a step of assaying a breast cancer tumour sample from the patient for expression of ADAM22, wherein expression of ADAM22 correlates with increased potential for metastasis compared with a patient who is ADAM22 negative. The invention also describes an agent for use in the treatment of metastatic breast cancer in a patient, in which the agent is selected from LGI1 protein (SEQ ID NO:1) and an LGI1 peptide mimic capable of mimicking the ADAM22 binding activity of LGI1 by binding to the LGI1 binding domain of ADAM22 (SEQ ID NO: 4) and which is capable of inhibiting migration of endocrine resistant breast cancer cells. | 01-29-2015 |
20150038430 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease. | 02-05-2015 |
20150051155 | PEPTIDOMIMETIC MACROCYCLES - Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein. | 02-19-2015 |
20150094271 | LEUCINE ZIPPER VARIANT AND USE THEREOF - A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant. | 04-02-2015 |
20150119337 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof. | 04-30-2015 |
20150141347 | MURINE ANTI-NY-ESO-1 T CELL RECEPTORS - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials. | 05-21-2015 |
20150291613 | FUNCTIONALIZED 9-BROMO-CAMPTOTHECIN DERIVATIVES - The present invention relates to new functionalized 9-bromo-camptothecin derivatives (I) which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them. The invention also relates to the use of these functionalized 9-bromo-camptothecin derivatives in the preparation of conjugates. | 10-15-2015 |
20150299265 | BINDING PROTEINS COMPRISING AT LEAST TWO REPEAT DOMAINS AGAINST HER2 - The present invention relates to a recombinant binding protein comprising at least a first and a second repeat domain, wherein each of said two repeat domains binds the extracellular region of HER2 and wherein said repeat domains are covalently linked. | 10-22-2015 |
20150335578 | LYOPHILIZED PREPARATIONS OF MELPHALAN FLUFENAMIDE - The present invention is directed to lyophilized pharmaceutical preparations comprising melphalan flufenamide, or pharmaceutically acceptable salts thereof, and sucrose. Further independent claims are directed to methods for their preparation, compositions comprising the lyophilized pharmaceutical preparations and their use in the treatment of cancer. | 11-26-2015 |
20150353642 | FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTION - Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment. | 12-10-2015 |
20150353935 | MELK Regulation for the Treatment of Breast Cancer - Methods for inhibiting growth or proliferation of breast cancer cells are provided. The methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. In some aspects, the methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. Methods of treatment for breast cancer and methods of identifying patients having cancer that are likely to benefit from treatment with a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor are also provided. | 12-10-2015 |
20150374796 | USE OF HAEMOGLOBIN OF ANNELIDS FOR TREATING CANCER - A method for treating cancer using at least one globin, a globin protomer or an extracellular haemoglobin of annelids. | 12-31-2015 |
20160000868 | RECEPTOR-TARGETING REAGENTS - The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), which are useful in, e.g., methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders such as, but not limited to, cancers and inflammatory disorders. Also featured are methods, compositions, and kits useful for selecting an appropriate treatment modality for a subject (e.g., a subject with a cancer or inflammatory disorder) and/or treating a variety of disorders such as cell proliferative disorders. | 01-07-2016 |
20160008424 | APOE PEPTIDE DIMERS AND USES THEREOF | 01-14-2016 |
20160022641 | Combination - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl)}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof. | 01-28-2016 |
20160024152 | CD44V6-Derived Peptides for Treating Breast Cancer - The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of breast cancer. | 01-28-2016 |
20160030515 | Use of Antisecretory Factors (AF) for Optimizing Cellular Uptake - The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition. | 02-04-2016 |
20160039872 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE - The invention provides novel compounds that may serve as anticancer therapeutics. The compounds of the invention bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds of the invention are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected pho-phoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives of the invention have achieved both good efficacy and an enhanced bioavailability. The invention also provides methods of use, compositions, and kits thereof. Further, the invention provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents. | 02-11-2016 |
20160045562 | Peptides for the Treatment of Cancer - The present invention relates to an isolated peptide for use in the treatment of cancer consisting of 12 to 50 amino acid residues comprising—at least two beta-strands, or—at least two alpha-helices or—at least one beta-strand and at least one alpha-helix, —wherein said beta-strands and/or alpha-helices are preferably separated from each other by at least one turn, wherein the peptide has a net positive charge of +7 or more; —wherein said peptide comprises at least one peptide moiety having amino acid sequence (X | 02-18-2016 |
20160058827 | COMBINATION ANTI-ESTROGEN RECEPTOR CANCER THERAPY USING MUC1 PEPTIDES AND CHEMOTHERAPEUTICS - The invention provides for treatment of MUC1+/ERα+/− cancers using an anti-MUC1 therapy, optionally including an anti-ERα therapy. In particular, the invention addresses the treatment of tamoxifen-resistant cancers, using MUC1+, and optionally anti-ERα therapy. | 03-03-2016 |
20160069882 | INHIBITORS OF PROTEINS SPECIFIC FOR THE SECRETOME OF A CHONDROCYTE FOR USE IN THE TREATMENT OF BREAST CANCER METASTASIS - The present invention relates to a method for identifying inhibitors of breast cancer metastasis based on a screening with proteins that are specific for the secretome of a chondrocyte, preferably cytokines and/or chemokines. The ligands as identified lead to a decrease of the migration and/or a re-differentiation of a breast cancer cell and/or a reduction of the number and/or size of breast cancer metastases. The present invention further relates to a method for detecting breast cancer metastasis, comprising the step of detecting at least one protein that is specific for the secretome of a chondrocyte, and for methods for treating and/or preventing breast cancer metastasis in a patient in need thereof, comprising the step of administering an effective amount of at least one ligand for one protein that is specific for the secretome of a chondrocyte to said patient in need thereof. | 03-10-2016 |
20160081981 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF - The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof. | 03-24-2016 |
20160096877 | APOE PEPTIDE DIMERS AND USES THEREOF - The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed. | 04-07-2016 |
20160136228 | COMPOSITIONS INCLUDING TRICIRIBINE AND BORTEZOMIB AND DERIVATIVES THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 05-19-2016 |
20160136230 | NOVEL COMPOUNDS - A compound of formula (I): | 05-19-2016 |
20160151456 | LIPOPEPTIDE INHIBITORS OF RAS ONCOPROTEINS | 06-02-2016 |
20160152665 | Compositions and Methods of Treatment of Cancers | 06-02-2016 |
20160168195 | OLIGOPEPTIDES AND PROCESS FOR PREPARATION THEREOF | 06-16-2016 |
20160184383 | METHOD OF TREATING CANCER - The present invention provides a method of treating cancer in a subject wherein the method comprising administering to the subject an IAP antagonist and a p38 and/or a MK2 inhibitor. | 06-30-2016 |
20160193283 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | 07-07-2016 |
20160199434 | COMPOSITIONS AND METHODS FOR MODULATING DNA METHYLATION | 07-14-2016 |
20160199442 | Anti- P2X7 Peptides and Epitopes | 07-14-2016 |
20160250289 | Galectin-3C Combination Therapy for Human Cancer | 09-01-2016 |
20160375086 | Combination - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof. | 12-29-2016 |
20170233702 | ERK-DERIVED PEPTIDES AND USES THEREOF | 08-17-2017 |
20180021403 | Combination Therapy | 01-25-2018 |